A review on nanotechnology based innovations in diagnosis and treatment of multiple sclerosis

Comston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Weinshenker, 1996, Epidemiology of multiple sclerosis, Neurol Clin, 142, 1 Khare, 2014, Prospects of brain machine interface in motor disabilities: the future support for multiple sclerosis patient to improve quality of life, Ann Med Health Sci Res, 4, 305, 10.4103/2141-9248.133447 Hauser, 2008, 2611 Cree, 2007, Multiple sclerosis Hemmer, 2002, New concepts in the immunopathogenesis of multiple sclerosis, Rev Neurosci, 3, 291, 10.1038/nrn784 Carrieri, 2008, Multiple sclerosis and Systemic Sclerosis: efficacy of interferon beta on skin lesions, Ann Rheum Dis, 67, 1192, 10.1136/ard.2008.087973 Miller, 2012, Clinically isolated syndromes, Lancet Neurol, 11, 157, 10.1016/S1474-4422(11)70274-5 Ascherio, 2007, Environmental risk factors for multiple sclerosis, Part I: the role of infection, Ann Neurol, 61, 288, 10.1002/ana.21117 Mowry, 2011, Natural history of multiple sclerosis: early prognostic factors, Neurol Clin, 29, 279, 10.1016/j.ncl.2011.01.001 Vukusic, 2007, Natural history of multiple sclerosis: risk factors and prognostic indicators, Curr Opin Neurol, 20, 269, 10.1097/WCO.0b013e32812583ad Lublin, 2005, Clinical features and diagnosis of multiple sclerosis, Neurol Clin, 23, 1, 10.1016/j.ncl.2004.09.003 Orive, 2009, Biomaterials for promoting brain protection, repair and regeneration, Rev Neurosci, 10, 682, 10.1038/nrn2685 Mansoori, 2007, Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead, World Rev Sci, 4, 226 Jain, 2005, The role of nanobiotechnology in drug discovery, Drug Discov Today, 10, 1435, 10.1016/S1359-6446(05)03573-7 Hu, 2010, Nanoparticle-assisted combination therapies for effective cancer treatment, Ther. Delivery, 1, 323, 10.4155/tde.10.13 Codarri, 2010, Cytokine networks in multiple sclerosis: lost in translation, Curr Opin Neurol, 23, 205, 10.1097/WCO.0b013e3283391feb Singh, 2011, Quantitative characterization of the influence of the nanoscale morphology of nanostructured surface on bacterial adhesion and biofilm formation, PLoS One, 6, 10.1371/journal.pone.0025029 Singh, 2017, Hydrophobic pinning with copper nanowhiskers leads to bactericidal properties, PLoS One, 12 Gandhi, 2010, Role of the innate immune system in the pathogenesis of multiple sclerosis, J Neuroimmunol, 22, 7, 10.1016/j.jneuroim.2009.10.015 Weber, 2007, Type II monocytes modulate T cell-mediated central nervous system autoimmune disease, Nat Med, 13, 935, 10.1038/nm1620 Barcellos, 2003, HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course, Multiple Sclerosis Genetics Group, Am J Hum Genet, 73, 710, 10.1086/367781 Bogdan, 2013, Pathology of multiple sclerosis: where do we stand, Continuum (Minneap Minn), 19, 901 Singh, 2009, Anomalous venous blood flow and iron deposition in multiple sclerosis, J Cereb Blood flow Metab, 29, 1867, 10.1038/jcbfm.2009.180 Frischer, 2009, The relation between inflammation and neurodegeneration in multiple sclerosis brains, Brain, 132, 1175, 10.1093/brain/awp070 Singh, 2010, Multiple sclerosis takes venous route: CCSVI and liberation therapy, Indian J Med Sci, 64, 337, 10.4103/0019-5359.99879 Cua, 2003, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421, 744, 10.1038/nature01355 Kasper, 2010, Multiple sclerosis immunology: the healthy immune system vs the MS immune system, Neurology, 74, 2, 10.1212/WNL.0b013e3181c97c8f Bielekova, 2000, Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand, Nat Med, 6, 1167, 10.1038/80516 Dolgin, 2010, The inverse of immunity, Nat Med, 16, 740, 10.1038/nm0710-740 Chastain, 2011, The role of antigen presenting cells in multiple sclerosis, Biochim Biophys Acta, 1821, 265, 10.1016/j.bbadis.2010.07.008 Slavin, 2001, Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity, J Clin Invest, 108, 1133, 10.1172/JCI13360 Bar-Or, 2007, Induction of antigen-specific tolerance in multiple sclerosisafter immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial, Arch Neurol, 64, 1407, 10.1001/archneur.64.10.nct70002 Brucklacher-Waldert, 2009, Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis, Brain, 132, 3329, 10.1093/brain/awp289 Durelli, 2009, T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta, Ann Neurol, 65, 499, 10.1002/ana.21652 Becher, 2006, Antigen presentation in autoimmunity and CNS inflammation:how T lymphocytes recognize the brain, J Mol Med, 84, 532, 10.1007/s00109-006-0065-1 Kebir, 2007, Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation, Nat Med, 13, 1173, 10.1038/nm1651 Nave, 2008, Axon-glial signaling and the glial support of axon function, Annu Rev Neurosci, 31, 535, 10.1146/annurev.neuro.30.051606.094309 O'Connor, 2005, Antibodies from inflamed central nervous system tissue recognizes myelin oligodendrocyte glycoprotein, J Immunol, 175, 1974, 10.4049/jimmunol.175.3.1974 O'Connor, 2010, The dual nature of T(H)17 cells: shifting the focus to function, Nat Immunol, 11, 471, 10.1038/ni.1882 Narges, 2017, Multiple sclerosis: immunopathology and treatment update, Brain Sci, 7, 1 Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X Tysabri® (natalizumab), prescribing information. Cambridge, Mass.: Biogen Idec; September 2011. Available at: www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed August 14, 2017. Hans, 2012, Progressive multiple sclerosis: pathology and pathogenesis, Nat Rev Neurol, 8, 647, 10.1038/nrneurol.2012.168 Dhib-Jalbut, 2010, Interferon-beta mechanisms of action in multiple sclerosis, Neurology, 74, S17, 10.1212/WNL.0b013e3181c97d99 2001, PRISMS study Group and the university of british columbia MS/MRI analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS, Neurology, 56, 1628, 10.1212/WNL.56.12.1628 Paty, 1993, Interferon beta-1b is effective in relapsing– remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 662, 10.1212/WNL.43.4.662 Racke, 2010, The mechanism of action of glatiramer acetate treatment in multiple sclerosis, Neurology, 74, S25, 10.1212/WNL.0b013e3181c97e39 Rice, 1999, Treatment with interferon beta-1b improves quality of life in multiple sclerosis, Can J Neurol Sci, 26, 276, 10.1017/S031716710000038X Fischer, 2000, Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis, Ann Neurol, 48, 885, 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1 Papadopoulou, 2012, Teriflunomide for oral therapy in multiple sclerosis, Expert Rev Clin Pharmacol, 5, 617, 10.1586/ecp.12.56 Rosenkranz, 2015, PML in a patient with lymphocytopenia treated with dimethyl fumarate, N Engl J Med, 372, 1476, 10.1056/NEJMc1415408 Linker, 2013, Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects, Curr Neurol Neurosci Rep, 13, 394, 10.1007/s11910-013-0394-8 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, the Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, 39, 285, 10.1002/ana.410390304 Polman, 2005, Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis, Neurology, 64, 987, 10.1212/01.WNL.0000154520.48391.69 Kappos, 2011, Ocrelizumab in relapsing–remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet, 378, 1779, 10.1016/S0140-6736(11)61649-8 Aharoni, 1997, Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis, Proc Natl Acad Sci, USA, 94, 10821, 10.1073/pnas.94.20.10821 Ford, 2010, Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate, Mult Scler, 16, 342, 10.1177/1352458509358088 Martinelli, 2009, Mitoxantrone: benefits and risks in multiple sclerosis patients, Neurol Sci, 30, S167, 10.1007/s10072-009-0142-7 Berger, 2010, Progressive multifocal leukoencephalopathy and newer biological agents, Drug Saf, 33, 969, 10.2165/11537510-000000000-00000 Coelho, 2007, The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors, J Pharmacol ExpTher, 323, 626, 10.1124/jpet.107.123927 Miron, 2008, FTY720 modulates human oligodendrocyte progenitor process extension and survival, Ann Neurol, 63, 61, 10.1002/ana.21227 O'Connor, 2011, For the TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis, N Engl J Med, 365, 1293, 10.1056/NEJMoa1014656 Wierinckx, 2005, Detoxication enzyme inducers modify cytokine production in rat mixed glial cells, J Neuroimmunol, 166, 132, 10.1016/j.jneuroim.2005.05.013 Cossburn, 2011, Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort, Neurology, 77, 573, 10.1212/WNL.0b013e318228bec5 Wanda, 2012, Current and emerging therapies in multiple sclerosis: a systematic review, Ther Adv Neurol Disord, 5, 205, 10.1177/1756285612450936 Mansoori, 2010, Cancerous cells targeting and folate: a comparative study of two folate conjugated gold nanoparticles for cancer nanotechnology applications, Cancers, 4, 1911, 10.3390/cancers2041911 Villar, 2005, Early differential diagnosis of multiple sclerosis using a new oligoclonal band test, Arch Neurol, 62, 574, 10.1001/archneur.62.4.574 Link, 2006, Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness, J Neuroimmunol, 180, 17, 10.1016/j.jneuroim.2006.07.006 Singh, 2012, Theranostic implications of Nanotechnology in multiple sclerosis: a future perspective, Autoimmune Dis, 2012, 160830 Stoeckli, 2012, What does the developing brain tell us about neural diseases?, Eur J Neurosci, 35, 1811, 10.1111/j.1460-9568.2012.08171.x Hassan, 2014, Biophysicochemical perspective of nanoparticle compatibility: a critically ignored parameter in nanomedicine, J Nanosci Nanotechnol, 14, 402, 10.1166/jnn.2014.8747 Singh, 2012, Biofilm formation on nanostructured titanium oxide surfaces and a micro/nanofabrication-based preventive strategy using colloidal lithography, Biofabrication, 4, 2484, 10.1088/1758-5082/4/2/025001 Singh, 2013, Interaction of bacterial cells with cluster-assembled nanostructured titania surfaces: an atomic force microscopy study, J Nanosci Nanotechnol, 13, 77, 10.1166/jnn.2013.6727 Tropea, 2010, Structural dynamics of synapses in vivo correlate with functional changes during experience-dependent plasticity in visual cortex, J Neurosci, 30, 11086, 10.1523/JNEUROSCI.1661-10.2010 Nunes, 2012, Therapeutics, imaging and toxicity of nanomaterials in the central nervous system, J Control Release, 161, 190, 10.1016/j.jconrel.2012.03.026 Singh, 2013, Micro-nanopatterning as tool to study the role of physicochemical properties on cell-surface interactions, J Biomed Mater Res A, 10, 3019, 10.1002/jbm.a.34586 Tucker, 2004, Neuroimaging in human immunodeficiency virus infection, J Neuroimmunol, 157, 153, 10.1016/j.jneuroim.2004.08.036 Bocti, 2006, Topographical patterns of lobar atrophy in frontotemporal dementia and Alzheimer's disease, Dement Geriatr Cognit Disord, 21, 364, 10.1159/000091838 Silverman, 2005, PET imaging in the assessment of normal and impaired cognitive function, Radiol Clin, 43, 67, 10.1016/j.rcl.2004.09.012 Wearne, 2005, New techniques for imaging, digitization and analysis of three-dimensional neural morphology on multiple scales, Neuroscience, 136, 661, 10.1016/j.neuroscience.2005.05.053 Silva, 2006, Neuroscience nanotechnology: progress, opportunities and challenges, Nat Rev Neurosci, 7, 65, 10.1038/nrn1827 Burn, 2003, Use of functional imaging in Parkinsonism and dementia, Mov Disord, 18, S88, 10.1002/mds.10568 Khachaturian, 2006, Diagnosis of Alzheimer's disease: two-decades of progress, J Alzheimers Dis, 9, 409, 10.3233/JAD-2006-9S346 Thompson, 2005, Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline, Proc Natl Acad Sci USA, 102, 15647, 10.1073/pnas.0502548102 Walker, 2005, Imaging in neurodegenerative disorders: recent studies, Curr Opin Psychiatr, 18, 640, 10.1097/01.yco.0000184417.29082.ea Binyamin, 2015, Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant, Int J Nanomed, 10, 7165 Singh, 2018, Three dimensional patterning in biomedicine: importance and application in neuropharmacology, J Biomed Mater Res B Appl Biomater, 106, 1369, 10.1002/jbm.b.33922 Singh, 2016, Top-down versus bottom-up nanoengineering routes to design advanced oropharmacological products, Curr Pharmaceut Des, 22, 1534, 10.2174/1381612822666151210124001 Singh, 2015, Astrocytes increase ATP exocytosis mediated calcium signaling in response to microgroove structures, Sci Rep, 5, 7847, 10.1038/srep07847 Han, 2016, Increased nanoparticle delivery to brain tumors by autocatalytic priming for improved treatment and imaging, ACS Nano, 10, 4209, 10.1021/acsnano.5b07573 Choonara, 2016, Improving drug delivery technology for treating neurodegenerative disease, Expert Opin Drug Deliv, 13, 1029, 10.1517/17425247.2016.1162152 Singh, 2017, Microemulsion based soft bacteria driven microswimmers for active cargo delivery, ACS Nano, 11, 9759, 10.1021/acsnano.7b02082 Gidwani, 2014, Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges, Curr Pharmaceut Biotechnol, 14, 1201, 10.2174/1389201015666140508122558 Singh, 2016, Recent trends in nano-biotechnology reinforcing contemporary pharmaceutical design, Curr Pharmaceut Des, 22, 1415, 10.2174/1381612822999160122121713 Ali, 2004, A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties, Free Radic Biol Med, 37, 1191, 10.1016/j.freeradbiomed.2004.07.002 Das, 2007, Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons, Biomaterials, 28, 1918, 10.1016/j.biomaterials.2006.11.036 Jin, 2011, Neurite outgrowth of dorsal root ganglia neurons is enhanced on aligned nanofibrous biopolymer scaffold with carbon nanotube coating, Neurosci Lett, 501, 10, 10.1016/j.neulet.2011.06.023 Liu, 2011, Peripheral nerve regeneration using composite poly(lactic acid-caprolactone)/nerve growth factor conduits prepared by coaxial electrospinning, J Biomed Mater Res A, 96, 13, 10.1002/jbm.a.32946 Modi, 2009, Nanotechnological applications for the treatment of neurodegenerative disorders, Prog Neurobiol, 88, 272, 10.1016/j.pneurobio.2009.05.002 Mayank, 2014, MMP-9 inhibition: a therapeutic strategy in ischemic stroke, Mol Neurobiol, 49, 563, 10.1007/s12035-013-8538-z Santiswarup, 2017, Peptide–MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices, Nat Nanotechnol, 12, 701, 10.1038/nnano.2017.56 Ada, 2012, Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis, Proc Natl Acad Sci, U S A, 109, 11270, 10.1073/pnas.1120611109 Belogurov, 2013, Liposome-encapsulated peptides protect against experimental allergic encephalitis, FASEB J, 27, 222, 10.1096/fj.12-213975 Leu, 2012, The effects of gold nanoparticles in wound healing with antioxidant epigallocatechingallate and α-lipoic acid, Nanomedicine, 8, 67 Orive, 2009, Biomaterials for promoting brain protection, repair and regeneration, Nat Rev Neurosci, 10, 682, 10.1038/nrn2685 Schubert, 2006, Cerium and yttrium oxide nanoparticles are neuroprotective, Biochem Biophys Res Commun, 342, 86, 10.1016/j.bbrc.2006.01.129 Dugan, 1997, Carboxyfullerenes as neuroprotective agents, Proc Natl Acad Sci USA, 94, 9434, 10.1073/pnas.94.17.9434 Ali, 2008, SOD activity of carboxyfullerenes predicts their neuroprotective efficacy: a structure-activity study, Nanomedicine, 4, 283, 10.1016/j.nano.2008.05.003 Li, 2007, Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population, J Neuroimmunol, 184, 227, 10.1016/j.jneuroim.2006.12.010 Kannan, 2012, Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model, Sci Transl Med, 4, 130, 10.1126/scitranslmed.3003162 Kizelsztein, 2009, Pegylatednanoliposomes remote-loaded with the anti-oxidant tempamineameliorate experimental autoimmune encephalomyelitis, J Neuroimmunol, 213, 20, 10.1016/j.jneuroim.2009.05.019 Kondiah, 2013, A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis, Int J Pharm, 456, 459, 10.1016/j.ijpharm.2013.08.038 Tan, 2011, Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine, Nanomedicine, 6, 1101, 10.2217/nnm.11.64 Bonoiu, 2009, MMP-9 gene silencing by a quantum dot-siRNAnanoplex delivery to maintain the integrity of the blood brain barrier, Brain Res, 1282, 142, 10.1016/j.brainres.2009.05.047 Burak, 2013, Myelin basic protein immunosensor for multiple sclerosis detection based upon label-free electrochemical impedance spectroscopy, Biosens Bioelectron, 46, 53, 10.1016/j.bios.2013.01.060 Derkus, 2014, Alginate and alginatetitanium dioxide nanocomposite as electrode materials for antimyelin basic protein immunosensing, Sensor Actuator B Chem, 192, 294, 10.1016/j.snb.2013.10.128 Millward, 2013, Iron oxide magnetic nanoparticles highlight early involvement of the choroid plexus in central nervous system inflammation, Ann Neurosci, 5 Singh, 2010, Interplay of iron metallobiology, metalloproteinases, and FXIII, and role of their gene variants in venous leg ulcer, Int J Low Extrem Wounds, 9, 166, 10.1177/1534734610384653 Raymond, 2016, Cellular and nuclear alignment analysis for determining epithelial cell chirality, Ann Biomed Eng, 44, 1575, 10.1007/s10439-015-1431-3 Singh, 2014, Carbon nanotube-induced loss of multicellular chirality on micropatterned substrate is mediated by oxidative stress, Acs Nano, 8, 2196, 10.1021/nn405253d Luchetti, 2012, Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain, Mol Imag, 11, 114, 10.2310/7290.2011.00032 Heta, 2012, Gadolinium containing photochromic micelles as potential magnetic resonance imaging traceable drug carriers, Photochem Photobiol, 88, 876, 10.1111/j.1751-1097.2012.01124.x Richards, 2012, In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humans, Circ Cardiovasc Imaging, 5, 509, 10.1161/CIRCIMAGING.112.972596 Radu, 2011, Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes, ACS Chem Neuro Sci, 2, 687, 10.1021/cn2000603 Weissleder, 1990, Ultra small superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging, Radiology, 175, 489, 10.1148/radiology.175.2.2326474 Haick, 2013 Nisreen, 2016, Silicon nanowire sensors enable diagnosis of patients via exhaled breath, ACS Nano, 10, 7047, 10.1021/acsnano.6b03127 Watson, 2009 Barenholz, 2006 Avtushenko, 2011 Josbert, 2010 Barenholz, 2015 Gabivov, 2015 Luger, 2015 Santamaria, 2014 Karaborni, 2015 Metselaar, 2011 Haick, 2013 Smriti, 2016, Formulation and optimization of Chitosan nanoparticles of dimethyl fumarate using Box- behnken Design, Int J Appl Pharm, 8, 10